|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chemotherapy in advanced ovarian cancer:an overview of randomized clinical trials显示文摘 | Advanced Ovarian Cancer Trialist Group | 1991 | BMJ1991，303，： | 1 |
| 2 | A phase I trial of the AGO-OVAR显示文摘 | Pfisterer J Du BA Sehouli J : The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer | 2006 | Ann Oncol2006，17，10： | 1 |
| 3 | A clinicopathologic analysis of fourteen cases显示文摘 | Clement PB Scully RE Uterine tumors resembling ovarian sex-cord tumors | | 0，，： | 1 |
| 4 | Pre-operative markers and treatment results显示文摘 | Tserkezoglou A Kontou S Hadjieleftheriou G et ai Primary andmetastatic ovarian cancer in patients with prior breast carcinoma | 2006 | Anticancer Res2006，26，3： | 1 |
| 5 | a pilot randomized controlled trial显示文摘 | Jacobs U Skates SJ MacDonald N Screening for ovarian cancer: | 1999 | Zancet1999，353，： | 1 |
| 6 | Case report and review of the subject 显示文摘 | Rodriguez-Martinez H A Lopez-Vancell D Perez-Olvera O et ak Ovarian pregnancy | 2012 | Rev Med Inst Mex Seguro Soc2012，50，2： | 1 |
| 7 | Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the Ⅰ-CON3 randomised trial显示文摘 | International Collaborative Ovarian Neoplasm Group | 2002 | Lancet2002，360，： | 1 |
| 8 | A suggestion for a recombinant FSH dosage normogram显示文摘 | Popovic - Todorovic B Loft A Lindhard A et aL A prospective study of predictive factors of ovarian response in' standard' IVF/ICSI pa- tients treated with recombinant FSH | 2003 | Hum Repord2003，18，4： | 1 |
| 9 | Br显示文摘 | Bartlett JM Rabiasz GJ Scott WN Transfonning growth factor-beta mRNA expression and growth control of hmnan ovarian carcinoma ceils | 2002 | cmncer2002，65，5： | 1 |
| 10 | A report of 30 cases显示文摘 | Szyfelbein W M Young R H Scully R E: Struma ovarii simulating ovarian tumors of other types | 1995 | Am J Surg Pathol1995，19，1： | 1 |
| 11 | Reeves,Ovarian cancer and oral contraceptives:collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls显示文摘 | Collaborative Group on Epidemiological Studies of Ovarian Cancer Beral V Doll R | | 0，，9609： | 1 |
| 12 | Menopausal hormone use and ovarian cancer risk: individual partici- pant meta-analysis of 52 epidemiological studies 显示文摘 | Collaborative Group on Epidemiological Studies of Ovarian Cancer | 2015 | Lancet2015，385，9980： | 1 |
| 13 | Ovarian cancer:screening,treatment and follow-up显示文摘 | NIH Consensus Development Panel on Ovarian Cancer | 1995 | JAMA1995，273，： | 1 |
| 14 | Premature ovarian failure:frequency and risk fac- tors among women attending a network of menopause clin- ics in Italy 显示文摘 | Premature ovarian failure:frequency and risk factors a- mong women attending a network of menopause clinics in Italy | 2003 | B JOG2003，110，1： | 1 |
| 15 | Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide,doxorubicin and cisplatin in women with ovarian cancer:the ICON3 randomized trial显示文摘 | The International Collaborative Ovarian Neoplasm (ICON) Group | 2002 | Lancet2002，360，： | 1 |
| 16 | Chemotherapy in ad-vanced ovarian cancer: An overview of randomised clinical trials显示文摘 | Advanced Ovarian Cancer Trialists Group | 1991 | BMJ1991，303，： | 1 |
| 17 | Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23257 women with ovarian cancer and 87303 controls显示文摘 | Collaborative Group on Epidemiological Studies of Ovarian Cancer | 2008 | Lancet2008，371，9609： | 1 |
| 18 | Paclitaxel plus Carboplatin versus standard chemotherapy with either single - agent Carboplatin or Cyclophosphamide,Doxorubicin,and Cisplatin in women with ovarian cancer: the ICON3 randomised trial 显示文摘 | The International Collaborative Ovarian Neoplasm Group (ICON Investigator) | 2002 | Lancet2002，360，3： | 1 |
| 19 | Nuclear size distinguishes serous carcinoma and predicts outcome 显示文摘 | Hsu CY Kurman R J Vang R low- from high-grade ovarian | 2005 | Hum Pathol2005，36，10： | 1 |
| 20 | Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin,and cisplatin in women with ovarian cancer: the ICON3 randomised trial 显示文摘 | International Collaborative Ovarian Neoplasm Group | 2002 | Lancet2002，360，9332： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员